Literature DB >> 22760866

Elevated ApoB serum levels strongly predict early cardiovascular events.

Bruna Gigante1, Karin Leander, Max Vikstrom, Paolo Frumento, Axel C Carlsson, Matteo Bottai, Ulf de Faire.   

Abstract

OBJECTIVE: ApoB exerts a pro-thrombotic and pro-atherogenic effect and promotes the progression of atherosclerotic lesions. In the present study, we investigated if elevated ApoB serum levels predicted the risk of premature cardiovascular events in a prospective Swedish cohort study of 60-year-old men and women from Stockholm.
DESIGN: A cohort consisting of every third man and woman turning 60 years of age in the large Stockholm area during the years 1997-1998 (n=4232).
METHODS: Incident cases of cardiovascular diseases have been recorded yearly by matching national registries. Exposure to high ApoB serum levels (≥0.9 g/l) was used to calculate the risk of cardiovascular diseases, and the time to the first cardiovascular event using Cox regression and Laplace regression, respectively.
RESULTS: Individuals exposed to high ApoB serum levels showed an increased risk of cardiovascular diseases over the 11 years of follow-up. The HR decreased over time from 2.49 at 4 years of study entry (95% CI 1.31 to 4.69) to 1.36 at 11 years (95% CI 1.01 to 1.83), after adjusting for gender, diabetes, hypertension, smoking, obesity, HDL and triglyceride serum levels. The first 5% of the individuals had a cardiovascular event nearly 2 years earlier among those with ApoB ≥0.9 g/l than among those with ApoB <0.9 g/l (p=0.001).
CONCLUSIONS: Our data indicate that increased ApoB serum levels are important predictors of early cardiovascular events. It is possible that this reflects a shift over time in the effects of apoB from a more pro-thrombotic to a more pro-atherogenetic molecule.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760866     DOI: 10.1136/heartjnl-2012-301852

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review.

Authors:  Paramjit K Sandhu; Salma M A Musaad; Alan T Remaley; Stephanie S Buehler; Sonya Strider; James H Derzon; Hubert W Vesper; Anne Ranne; Colleen S Shaw; Robert H Christenson
Journal:  J Appl Lab Med       Date:  2016-08-01

2.  Association between serum apolipoprotein B and atrial fibrillation: a case-control study.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

3.  Effects of Drosophila melanogaster regular exercise and apolipoprotein B knockdown on abnormal heart rhythm induced by a high-fat diet.

Authors:  Meng Ding; Qui Fang Li; Guo Yin; Jing Lin Liu; Xiao Yi Jan; Ting Huang; Ai Chun Li; Lan Zheng
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

4.  Obesity, metabolic syndrome and risk of atrial fibrillation: a Swedish, prospective cohort study.

Authors:  Petter K Nyström; Axel C Carlsson; Karin Leander; Ulf de Faire; Mai-Lis Hellenius; Bruna Gigante
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

5.  Serum IL8 is not associated with cardiovascular events but with all-cause mortality.

Authors:  Ilais Moreno Velásquez; Ashwini Gajulapuri; Karin Leander; Anita Berglund; Ulf de Faire; Bruna Gigante
Journal:  BMC Cardiovasc Disord       Date:  2019-02-04       Impact factor: 2.298

6.  Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer's Disease and Cardiovascular Diseases.

Authors:  Chun Xu; Debra Garcia; Yongke Lu; Kaysie Ozuna; Donald A Adjeroh; Kesheng Wang
Journal:  Cells       Date:  2021-12-23       Impact factor: 6.600

7.  Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study.

Authors:  Göran Walldius; Ulf de Faire; Lars Alfredsson; Karin Leander; Peter Westerholm; Håkan Malmström; Torbjörn Ivert; Niklas Hammar
Journal:  PLoS Med       Date:  2021-12-01       Impact factor: 11.069

Review 8.  Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease.

Authors:  Chiara Vavassori; Eleonora Cipriani; Gualtiero Ivanoe Colombo
Journal:  Eur Cardiol       Date:  2022-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.